National
YEAR IN REVIEW: ‘Don’t Ask’ repeal is year’s top story
Rollercoaster fight ends with Obama’s signature
The passage of legislation to end the 17-year-old ban on service by open gays in the U.S. military after a year-long fight makes the “Don’t Ask, Don’t Tell” saga the story of the year for 2010.
Throughout the course of the year, supporters of “Don’t Ask, Don’t Tell” repeal endured a rollercoaster ride during which many observers predicted efforts to lift the military’s gay ban would end in failure.
In January, President Obama set up the path for repeal in his State of the Union address.
“This year, I will work with Congress and our military to finally repeal the law that denies gay Americans the right to serve the country they love because of who they are,” Obama said. “It’s the right thing to do.”
Efforts to repeal “Don’t Ask, Don’t Tell” got a significant boost in February during a Senate Armed Services Committee hearing when Chairman of the Joint Chiefs of Staff Adm. Mike Mullen announced that he personally supports the service of openly gay people in the U.S. military.
“It is my personal belief that allowing gays and lesbians to serve openly would be the right thing to do,” Mullen said. “No matter how I look at the issue, I cannot escape being troubled by the fact that we have in place a policy which forces young men and women to lie about who they are in order to defend their fellow citizens.”
Mullen’s support for ending “Don’t Ask, Don’t Tell” is seen by many as the lynchpin that ultimately led to repeal of the law because he is an authoritative voice in the military and was seen as outside the influence of LGBT advocates.
During the same hearing, Defense Secretary Robert Gates unveiled plans to establish a Pentagon working group study of “Don’t Ask, Don’t Tell” that would determine the best way to implement repeal of the law should Congress should take action. Gates appointed Jeh Johnson, the Pentagon’s general counsel, and Gen. Carter Ham, commander of U.S. Army Europe, as co-chairs of the working group, and directed them to produce a study by Dec. 1.
At the same hearing, U.S. senators opposed to “Don’t Ask, Don’t Tell” repeal expressed consternation over plans to move forward and Mullen’s declared support for allowing gays to serve openly in the armed forces.
Sen. John McCain (R-Ariz.) said he was “deeply disappointed” by Gates’ statement and the defense secretary’s plans to move forward with a study to determine how to implement repeal of “Don’t Ask, Don’t Tell” as opposed to whether it should be repealed.
As the study on implementing an end to “Don’t Ask, Don’t Tell” was underway, those seeking to end the law made plans to pass a repeal of the law as part of major defense budget legislation pending before Congress as part of the fiscal year 2011 defense authorization bill. In 1993, “Don’t Ask, Don’t Tell” was enacted into law as part of the defense authorization bill and LGBT advocates believed attaching a measure as part of defense spending legislation would bolster chances for success of repeal.
But the path to passage of repeal encountered a significant roadblock in April when Gates wrote a letter to Congress saying he’s “strongly opposed” to any legislative change to “Don’t Ask, Don’t Tell” before the Pentagon study is complete.
Many thought Gates had doomed any chances for legislative repeal of “Don’t Ask, Don’t Tell.” But repeal advocates came forth with a compromise measure that would institute an end to the law only after the Pentagon report was finished and the president, defense secretary and chairman of the Joint Chiefs of Staff certify that the U.S. military is ready.
The White House and Pentagon issued statements saying pursuing legislation after the Pentagon study is complete would be the ideal way to address repeal, but that they could support the proposed compromise legislation.
In May, the House attached the repeal measure as part of the defense authorization bill as an amendment by a vote of 234-194 before approving the legislation as a whole. On the same day, the Senate Armed Services Committee did the same to its version of the bill before reporting it out to the Senate floor.
On the House floor, Rep. Patrick Murphy (D-Pa.), an Iraq war veteran and the sponsor of repeal legislation, urged his colleagues to approve an end to the military’s gay ban.
Following the votes, the prospects for “Don’t Ask, Don’t Tell” repeal seemed bright. But the efforts to move forward with the legislation were stymied as the Senate didn’t take up the measure for months. In July, McCain objected to a motion to proceed to the defense authorization bill upon lawmakers’ return from August recess.
In September, Senate Majority Leader Harry Reid (D-Nev.) file cloture to proceed on the defense authorization bill regardless of the objections from any other senator.
At first, many LGBT advocates were confident that 60 votes were present in the U.S. Senate to proceed to defense legislation over McCain’s objection. But this support began to crumble away as many U.S. senators said they disapproved of the limited number of amendments that would be allowed.
On the Senate floor, Sen. Susan Collins (R-Maine), who voted for the repeal amendment in committee, was among those expressing discontent over the procedural conditions for the defense authorization.
The motion to proceed on the defense authorization bill failed 56-43, four votes short of the 60 votes necessary to proceed with the legislation. Reid pledged to bring up the legislation again, but the bill’s fate was uncertain.
When Republicans took control of the House in the November elections, it became clear that Congress needed to act before the end of the year.
With the legislative route to ending “Don’t Ask, Don’t Tell” in limbo, another route to end the military’s gay ban opened up in September when a California federal court ruled that the law was unconstitutional in the case of Log Cabin Republicans v. United States.
In October, U.S. District Court Judge Virginia Phillips affirmed her earlier ruling by issuing an injunction enjoining the U.S. government from the enforcement of “Don’t Ask, Don’t Tell.”
The U.S. Justice Department appealed the decision to the U.S. Ninth Circuit Court of Appeals and asked for a stay in the injunction, arguing that the Pentagon needs time to implement a repeal of the law.
On Oct. 21, the Ninth Circuit granted the stay in the injunction, ending the eight-day period in which gays could serve openly in the U.S. military.
But the court action put increased pressure on Congress to repeal “Don’t Ask, Don’t Tell” before the year was out. White House Press Secretary Robert Gibbs maintained Congress should repeal “Don’t Ask, Don’t Tell” legislatively before the courts strike down the statute to provide the Pentagon more wiggle-room with implementation.
Efforts to repeal “Don’t Ask, Don’t Tell” received another significant boost on Nov. 30 when the Pentagon finally released its study and found that repeal could be implemented with low risk to the armed forces over the long term.
The 256-page report included the results of survey sent out to 400,000 service members regarding openly gay people in the U.S. military. Of the more than 115,000 who responded, 70 percent said they believed repeal would have a positive, mixed or no effect on a unit’s ability to get the job done.
Hopes were high that with the Pentagon report, the Senate would be able to move forward with the defense authorization and “Don’t Ask, Don’t Tell” repeal. But those hopes were dashed on Dec. 9 when a motion to proceed on the defense authorization bill failed 57-40.
Immediately following the vote, Sen. Joseph Lieberman (I-Conn.) and Collins called a news conference and announced they would introduce stand-alone “Don’t Ask, Don’t Tell” legislation — a move seen by many as a “Hail Mary” pass to make repeal happen before the end of the year.
With limited time remaining in the lame duck session, the U.S. House on Dec. 15 approved “Don’t Ask, Don’t Tell” yet again as a standalone measure by a vote 250-175. The move enabled the House to send the legislation to the Senate as “privileged” bill, shaving off the first 30 hours of debate that would have otherwise been needed in the Senate.
After the Senate approved the extension of the Bush-era tax cuts, repeal advocates became optimistic that 60 votes were present to support the legislation as Sens. Scott Brown (R-Mass.), Lisa Murkowski (R-Alaska), Olympia Snowe (R-Maine) signaled they would support repeal.
On Dec. 18, repeal advocates finally cleared the last major hurdle for “Don’t Ask, Don’t Tell” when the Senate invoked cloture on the legislation by a vote of 63-33. On the same day, the Senate agreed to final passage of the bill by a vote of 65-31.
LGBT advocates heralded the Senate vote — the first time Congress has approved a pro-gay bill as a standalone measure — as an unprecedented accomplishment for LGBT Americans.
President Obama brought to a close on Dec. 22 the legislative journey to end “Don’t Ask, Don’t Tell” when he signed the repeal legislation into law.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
